All points
2184 words
- A new generation of genetic medicines can replace defective genes and stop previously fatal diseases. These therapies can transform or save children's lives, sometimes with a single dose, but individual treatments can cost between $2 million and $3.2 million. American healthcare has no settled way to finance treatments at this scale.
- Maisie Green was born in 2017 with spinal muscular atrophy (SMA). Her mother, CG Green, initially noticed that Maisie sounded permanently congested, almost as if she had a cold. By approximately two weeks old, Maisie could not hold her head up; her neck appeared completely floppy.
- A blood test finally identified Maisie's disease. A doctor tested her for SMA, a genetic condition caused by a missing or defective gene that leads to progressive muscle deterioration. When CG asked what could be done, the doctor reportedly shook her head and told her to love and squeeze her daughter.
- SMA carried an expectation of death before the age of two. Without effective treatment, the disease progressively destroys muscle function and can be fatal in early childhood. CG believed she was going to bury Maisie before her second birthday.
- Zolgensma offered Maisie a potentially life-saving treatment in 2019. The FDA approved the one-time gene therapy, which delivers a functioning replacement gene to help the child's cells produce the protein needed to address the disease. Its price was approximately $2 million for one dose.
- Maisie's Medicaid-managed insurance plan initially refused to cover Zolgensma. Although she was enrolled in her state's Medicaid program, the private insurance company administering her coverage declined payment. CG believed her daughter would die despite an available treatment because nobody would finance it.
- CG interpreted the insurance company's refusal as effectively choosing death over treatment. She described the situation as one in which it was cheaper for her daughter to die and accused the insurer of counting on that outcome. This was her interpretation of the refusal, not evidence that the insurer explicitly intended Maisie's death.
- CG launched a personal campaign to secure the treatment. She pursued philanthropic assistance, established a GoFundMe campaign and demanded a meeting with the insurance company. She specifically wanted its decision-makers to look her daughter in the eye and acknowledge the consequences of refusing treatment.
- The insurance company's board eventually reversed course. Following CG's campaign and confrontation, the board relented and Maisie received Zolgensma in 2019. The treatment consisted of a single infusion lasting approximately one hour.
- Maisie's response to gene therapy dramatically changed her family's future. CG described the effect as extraordinary and said the treatment changed both her daughter's life and the family's life. The progression of the disease subsequently appeared to stop.
- The treatment could not reverse damage already caused by SMA. When the programme met Maisie at six years old, she still could not walk because of the impairment sustained before treatment. However, she was making straight A's at school and could communicate and interact independently.
- CG had become a testimonial participant for the drug manufacturer. Her experience was sufficiently positive that she appeared in promotional testimonials for the company behind Zolgensma. Her daughter's outcome demonstrates the potential benefit of treatment, although it does not establish that every patient will experience the same result.
- More than 300 expensive genetic therapies were already in clinical trials. The emerging pipeline includes treatments for conditions affecting not just small groups of children but potentially millions of people. This raises the prospect that the financial problems seen with rare childhood diseases will eventually extend to much more common illnesses.
- MIT economist Jonathan Gruber warned of a coming financial crisis for employer-sponsored health insurance. Gruber, who chaired MIT's economics department and helped architect the Affordable Care Act, described the approaching wave of expensive genetic and cellular treatments as a tsunami that could overwhelm the existing insurance system.
- The biggest future challenge could come from treating common diseases. Gruber specifically identified cancer and heart disease as areas where genetic and cellular therapies could eventually become available. Their much larger patient populations could create financial obligations far beyond those associated with today's rare-disease treatments.
- Approximately two-thirds of insured Americans are covered by self-insured arrangements, according to Gruber. Under these arrangements, employers pay their employees' medical claims themselves rather than transferring the full financial risk to an insurance company. An insurer may administer the plan, but the employer ultimately bears the cost.
- Self-insured employers face a potentially devastating choice when an employee needs multimillion-dollar treatment. Covering a single therapy could expose a company to substantial financial losses or even bankruptcy. Refusing coverage, however, means denying an employee access to treatment that could save a life.
- Gruber identified this conflict as a structural problem rather than simply an insurance-company dispute. The existing employer-based financing model was not designed to absorb repeated multimillion-dollar payments for individual patients. The problem becomes more serious as additional gene therapies enter the market.
- Mike Poor faced this dilemma as CEO of Mosaic Life Care. Mosaic is a nonprofit hospital system in Missouri with approximately 5,000 employees. Poor argued that access to the best medical treatment should not depend on whether someone is wealthy.
- Mosaic decided in 2023 not to cover gene therapies. Poor said covering these treatments would have increased employee health insurance premiums by approximately $125 per month. The organisation therefore decided that the potential financial burden was too significant to absorb under its existing arrangement.
- The consequences became personal when a Mosaic employee had twins with SMA. A few months after the coverage decision, the employee's family needed gene therapy for both children. The combined treatment cost was approximately $4.2 million.
- Mosaic's insurance plan denied coverage for the twins' treatment. The family subsequently went public and blamed the hospital system for refusing to finance potentially life-saving medication. The dispute turned an internal insurance policy into a highly public controversy.
- Mike Poor and his family received death threats. Poor said that his family was threatened following the public controversy. He sent his family away for their protection while choosing to remain at the hospital and continue working to secure treatment for the children.
- Poor appealed directly to philanthropists and legislators after the insurance denial. Rather than abandoning the family, he pursued alternative funding through charitable and political channels. His efforts eventually helped bring state Medicaid into the situation.
- State Medicaid ultimately paid for the twins' gene therapy. The children obtained access to treatment through public funding rather than Mosaic's employee health plan. The case demonstrates how responsibility for expensive treatments can shift between employers, charitable organisations and government programmes.
- Poor regarded the twins' case as a warning about the future of American healthcare. He emphasised that the incident was only one situation but described it as a bellwether of what was coming. Each newly approved gene therapy seemed to establish another record for the most expensive medicine ever developed.
- Doug Ingram, CEO of Sarepta Therapeutics, defended the economics behind multimillion-dollar gene therapies. The company developed Elevidys, a gene therapy for Duchenne muscular dystrophy, a progressive muscle-wasting disease that predominantly affects boys. The treatment costs approximately $3.2 million for a single dose, which may be sufficient to provide lasting benefit.
- Duchenne muscular dystrophy traditionally leaves families with an extremely bleak prognosis. Parents are told that their sons will progressively lose muscle function and that the disease will eventually kill them. Ingram described the emotional reality of families being sent home with little more than advice to love their children as the disease advances.
- Elevidys uses an engineered gene to help muscle cells produce a protective protein. A modified virus acts as a delivery vehicle, transporting the genetic instructions into the child's cells. The treatment is intended to address the underlying genetic problem rather than simply manage symptoms.
- Developing Elevidys took approximately 18 years. Ingram said the company first had to establish whether the treatment could work safely, then solve the challenge of manufacturing it at scale. At the time, the global gene therapy manufacturing capacity of companies, research facilities and universities combined was insufficient for the capacity they calculated they would need.
- Sarepta had to raise billions of dollars before it could produce the treatment. Ingram said the company needed investors to finance an ambitious project whose eventual success was highly uncertain. It had to persuade investors to fund a future possibility rather than an already established commercial medicine.
- Ingram put the cost of developing Elevidys at approximately $3 billion. He said the investment reflected the scientific, manufacturing and financial challenges involved in bringing the therapy to market. The company now needs to recover that investment from a relatively small potential patient population.
- Duchenne muscular dystrophy affects approximately 15,000 people in the United States. Ingram argued that the limited market makes it particularly difficult to recover billions of dollars in development costs. Unlike a medicine for a common condition, the company cannot spread its investment across millions of potential customers.
- Ingram defended the current price while acknowledging that it should not represent the long-term standard. He argued that the $3.2 million price was justified in the context of development risk, manufacturing investment and the treatment's potential value. However, he explicitly said society should not be satisfied with gene therapies remaining this expensive indefinitely.
- Ingram cited the economics of drug development to explain why prices are so high. He said developing a therapy takes more than ten years on average and costs nearly $3 billion. At the beginning of development, the probability of successfully producing an approved treatment is extremely low, meaning companies must finance many unsuccessful possibilities alongside the few that eventually succeed.
- He argued that manufacturing experience should gradually reduce gene therapy costs. As companies produce more treatments and improve their manufacturing processes, production should become more efficient. Future competition between manufacturers could also reduce prices.
- Ingram identified federal regulatory requirements as another potential source of unnecessary expense. He argued that the FDA approval system has accumulated layers of requirements over 60–70 years. Although those requirements were introduced to protect safety and effectiveness, he believes some should be reconsidered in light of modern scientific knowledge.
- Ingram called for streamlining regulation rather than abandoning patient protection. His argument was that requirements should be reduced to those genuinely necessary, informed by current science rather than assumptions inherited from the 1960s. He believes this could improve the probability of successful development and reduce the cost of producing therapies.
- Elevidys had received FDA approval despite mixed clinical results. The treatment had already been administered to patients, and the programme reported two deaths from liver failure. The transcript's stated total number of treated patients is unclear, but approximately half of those treated were covered by Medicaid.
- The safety concerns complicate the economic argument for expensive gene therapies. Although these medicines may offer extraordinary benefits, their approval and commercial use do not eliminate the possibility of serious harm. The reported liver-failure deaths underline the importance of evaluating safety alongside the potential benefits.
- The programme could not yet establish Elevidys's overall effectiveness. It was too early to make a definitive assessment of how well the therapy worked across the treated population. The existence of positive individual outcomes did not resolve the wider clinical questions.
- One of the drug vials shown by Ingram had been prepared for a boy named Leighton. Several months after receiving treatment, Leighton's parents told the programme that he was thriving, stronger and more independent. His experience provided an encouraging individual example, rather than conclusive evidence of population-wide effectiveness.
- Ingram rejected the idea that either drug manufacturers or employers were necessarily the villains. When asked whether employers refusing coverage or pharmaceutical companies charging millions were responsible, he argued that neither side was inherently the bad actor. His position was that society had developed a new and extraordinarily expensive form of treatment without developing a corresponding way to pay for it.
- Gruber argued that government involvement and negotiated prices would be necessary to solve the financing problem. He believes society must develop a system that distributes the costs of these therapies more broadly instead of leaving individual employers to absorb potentially catastrophic expenses. Government support and negotiated drug prices were identified as important parts of the solution.
- The disagreement is ultimately about who should finance medical breakthroughs whose costs exceed the capacity of ordinary insurance arrangements. Drug companies argue that high prices reflect extraordinary research investment, development risk and limited patient populations. Employers face the immediate financial consequences, while families face the possibility of losing children when coverage is refused.
- Maisie's survival illustrates both the extraordinary promise and the financial failure of the emerging gene therapy system. A treatment that could stop a fatal disease existed in 2019, yet her family had to pursue philanthropy, public pressure and a confrontation with the insurer before obtaining it. The central problem was no longer simply whether medicine could save her, but whether the healthcare system would pay for it.